Health · Pharma & Biotech · 2 days ago
FDA Approves Pritelivir for Herpes Lesions in Some Immunocompromised Patients
The FDA has approved pritelivir, sold as Hovilpri, in tablet form.
It is for lesions caused by herpes simplex virus, or HSV.
These lesions affect the skin and mucous membranes.
The approval applies to immunocompromised patients whose lesions have not responded to other treatments.
This gives those patients an approved treatment option when other treatments have failed.
The available information does not say when the drug will become available or describe any next steps.
The FDA approved pritelivir tablets to treat herpes simplex virus lesions in some immunocompromised patients.
The approval is for patients whose mucocutaneous lesions have not responded to other treatments.
Pritelivir is marketed under the name Hovilpri.
- Who
- Immunocompromised patients with herpes simplex virus infections whose lesions have not responded to other treatments.
- What
- The FDA approved pritelivir tablets to treat mucocutaneous lesions.
- When
- The approval was reported on October 9, 2026; the exact approval date is not stated.
- Where
- Not stated.
- Why
- To treat mucocutaneous lesions caused by herpes simplex virus infections in patients who have not responded to other treatments.
This story does not have two clearly opposing sides.
No direct quotes in the coverage so far.
This story does not have a timeline yet.
- Drug
- Pritelivir tablets
- Brand name
- Hovilpri
- Regulator
- FDA
- Condition
- Mucocutaneous lesions caused by herpes simplex virus infections
- Eligible patients
- Immunocompromised patients who have not responded to other treatments
Sources
Related news
Experimental injection reduced visceral fat by 12% in early trials
AstraZeneca blames trial design for failed bone disease drug study
Baby Sleep Gripe Water Recalled After Alcohol Found in Testing
FDA Warns Amazon Over Unapproved Herpes Treatments
Possible Wrong Dose Raises Questions for PDE9 Drug Trials in Heart Failure
FDA approves atezolizumab with chemotherapy for some stage III colon cancers
Review links drug company gifts to more and less appropriate prescribing
Brazil suspends Peptistrong supplement and orders all batches recalled
Experimental eye drops improve vision in a small study of a rare eye disease
Taboos limit sales of weight-loss drugs in India despite obesity rates
Roche reports year-long results for eye drug Vamikibart
